RESEARCH TRIANGLE–Norak and Cellomics of Pittsburgh said they will jointly market Norak’s Transfluor licenses in North America and Europe.

Norak’s Transflour technology is a patented drug discovery technology designed to be the most direct and accurate method for screening potential drug candidates against G protein-coupled receptor targets (GPCRS).

GPCRS are an important protein family. Hundreds of drugs target pathways involving these receptors, including antihistamines, antidepressants, and antihypertensives. The functions of many of these proteins are unknown, and determining ligands and signaling pathways is time-consuming and expensive. Hence, the need for rapid screening methods such as Norak’s and Cellomics’.

Cellomics sells a variety of screening systems and will offer Norak’s technology along with several of its own products.

Norak is utilizing its proprietary Transfluor technology to become a world leader in the discovery and development of drugs that regulate G protein-coupled receptors.

Norak Biosciences